Streetbeat News

Analyst Ratings

CB

BMO Capital analyst Michael Zaremski has maintained a 'Market Perform' rating on Chubb (NYSE:CB) and increased the price target from $220 to $240.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:59 pm

CHTR

Charter Communications, Inc (NASDAQ:CHTR) reported weaker-than-expected Q4 earnings, with revenue slightly above consensus but EPS below expectations. The company saw growth in Internet, Mobile service, and Commercial sectors, and expects higher Capex for 2024. Shares fell 16.5% after the announcement. Analysts from JP Morgan and Barclays adjusted their price targets and ratings for CHTR following the earnings report.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:58 pm

ABBV

BMO Capital analyst Evan David Seigerman maintains an Outperform rating on AbbVie (NYSE:ABBV) and raises the price target from $187 to $195.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:57 pm

ACAD

Oppenheimer analyst Jay Olson has reiterated a 'Perform' rating on ACADIA Pharmaceuticals (ACAD) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:53 pm

TEVA

Barclays analyst Balaji Prasad maintains an Overweight rating on Teva Pharmaceutical Industries (TEVA) and raises the price target from $15 to $17.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:53 pm

WT

Oppenheimer analyst Chris Kotowski maintains an Outperform rating on WisdomTree (NYSE:WT) and raises the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:51 pm

ABBV

AbbVie Inc (NYSE:ABBV) reported Q4 earnings surpassing expectations with adjusted EPS of $2.79 and net revenues of $14.301 billion. The company also completed the acquisition of ImmunoGen, enhancing its cancer therapy portfolio. AbbVie raised its long-term revenue outlook for Skyrizi and Rinvoq, expecting over $27 billion by 2027. Analysts from Barclays and Raymond James increased their price targets for AbbVie following these results. AbbVie's stock rose 0.6% to close at $168.67.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:50 pm

ROP

Barclays analyst Julian Mitchell has maintained an Overweight rating on Roper Technologies (NASDAQ:ROP) and increased the price target from $580 to $596.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:45 pm

EXPE

Oppenheimer analyst Jed Kelly has reiterated an Outperform rating on Expedia Group (NASDAQ:EXPE), maintaining a price target of $175.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 1:45 pm

CBOE

Cboe Global Markets, Inc. (NYSE:CBOE) exceeded Q4 earnings expectations with $2.06 per share against the forecasted $2.03, despite sales missing estimates at $499.00 million versus $511.68 million expected. The company anticipates 5% to 7% organic net revenue growth for FY24. Following the report, shares dropped by 1.1% to $182.78. Analysts from Barclays, Rosenblatt, and Oppenheimer adjusted their price targets, with changes reflecting both increases and decreases but maintaining positive ratings.

Portfolio Pulse from Avi Kapoor

February 05, 2024 | 1:45 pm